• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Galapagos NV

    8/23/24 4:01:26 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLPG alert in real time by email
    SC 13D 1 tm2422362d1_sc13d.htm SC 13D

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

     

    Galapagos NV

    (Name of Issuer)

     

    Ordinary Shares, no par value

    (Title of Class of Securities)

     

    36315X101

    (CUSIP Number)

     

    Oleg Nodelman

    EcoR1 Capital, LLC

    357 Tehama Street #3

    San Fransisco, CA 94103

    (415) 448-6534

     

    with a copy to

     

    Richard M. Brand

    Erica L. Hogan

    Cadwalader, Wickersham & Taft LLP

    200 Liberty Street

    New York, NY 10281

    (212) 504-6000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    August 19, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. x

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

      1.

    Names of Reporting Persons

    EcoR1 Capital, LLC

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) x
      3. SEC Use Only
      4.

    Source of Funds (See Instructions)

    AF

      5. Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
      6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    6,505,8901

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    6,505,8901

      11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    6,505,8901

      12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
      13.

    Percent of Class Represented by Amount in Row (11)

    9.9%*

      14.

    Type of Reporting Person (See Instructions)

    OO, IA

                      

    1 The amounts reported include (1) ordinary shares, no par value, of Galapagos NV (the “Issuer”) and (2) American Depositary Shares, each of which represents one ordinary share, no par value, of the Issuer.

    * All percentage calculations set forth herein are based on 65,897,071 ordinary shares, no par value, of the Issuer issued and outstanding as of December 31, 2023, as reported in the Issuer’s Form 20-F filed with the U.S. Securities and Exchange Commission on March 28, 2024 (the “Form 20-F”). 

     

     

     

     

      1.

    Names of Reporting Persons

    Oleg Nodelman

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) x
      3. SEC Use Only
      4.

    Source of Funds (See Instructions)

    AF

      5. Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
      6.

    Citizenship or Place of Organization

    United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    6,505,8901

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    6,505,8901

      11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    6,505,8901

      12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
      13.

    Percent of Class Represented by Amount in Row (11)

    9.9%*

      14.

    Type of Reporting Person (See Instructions)

    IN

                      

    1 The amounts reported above include (1) ordinary shares, no par value, of the Issuer and (2) American Depositary Shares, each of which represents one ordinary share, no par value, of the Issuer.

    * All percentage calculations set forth herein are based on 65,897,071 ordinary shares, no par value, of the Issuer issued and outstanding as of December 31, 2023, as reported in the Form 20-F.

     

     

     

     

      1.

    Names of Reporting Persons

    EcoR1 Capital Fund Qualified, L.P.

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) x
      3. SEC Use Only
      4.

    Source of Funds (See Instructions)

    WC

      5. Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
      6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    6,121,3381

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    6,121,3381

      11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    6,121,3381

      12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
      13.

    Percent of Class Represented by Amount in Row (11)

    9.3%*

      14.

    Type of Reporting Person (See Instructions)

    PN

                      

    1 The amounts reported above include (1) ordinary shares, no par value, of the Issuer and (2) American Depositary Shares, each of which represents one ordinary share of the Issuer.

    * All percentage calculations set forth herein are based on 65,897,071 ordinary shares, no par value, of the Issuer issued and outstanding as of December 31, 2023, as reported in the Form 20-F.

     

     

     

     

      1.

    Names of Reporting Persons

    EcoR1 Capital Fund L.P.

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) x
      3. SEC Use Only
      4.

    Source of Funds (See Instructions)

    WC

      5. Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) o
      6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    384,5521

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    384,5521

      11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    384,5521

      12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) o
      13.

    Percent of Class Represented by Amount in Row (11)

    0.6%*

      14.

    Type of Reporting Person (See Instructions)

    PN

                        

    1 The amounts reported above include (1) ordinary shares, no par value, of the Issuer and (2) American Depositary Shares, each of which represents one ordinary share of the Issuer.

    * All percentage calculations set forth herein are based on 65,897,071 ordinary shares, no par value, of the Issuer issued and outstanding as of December 31, 2023, as reported in the Form 20-F.

     

     

     

     

    Item 1. Security and Issuer.

     

    This statement on Schedule 13D (“Schedule 13D”) relates to ordinary shares, no par value, and American Depositary Shares, each of which represents one ordinary share, no par value, of the Issuer (together, the “Ordinary Shares”). The principal executive offices of the Issuer are located at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium.

     

    Each Reporting Person (defined in Item 2 below) is filing this statement jointly with each of the other Reporting Persons and may be deemed to be included in a “group” within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, with each of the other Reporting Persons. Each Reporting Person expressly disclaims membership in a group with any other person other than the other Reporting Persons.

     

    Each Reporting Person disclaims beneficial ownership of the Subject Shares (defined in Item 5 below) except to the extent of such Reporting Person’s pecuniary interest therein.

     

    Item 2. Identity and Background.

     

    (a), (f) This Schedule 13D is being filed by:

     

    (i) EcoR1 Capital, LLC, a Delaware limited liability company (“EcoR1”);
       
    (ii) Oleg Nodelman, a citizen of the United States of America (“Mr. Nodelman”);
       
    (iii) EcoR1 Capital Fund Qualified, L.P. , a Delaware limited partnership (the “Qualified Fund”); and
       
    (iv) EcoR1 Capital Fund, L.P., a Delaware limited partnership (the “Capital Fund” and, together with EcoR1, Mr. Nodelman, and Qualified Fund, the “Reporting Persons”).

     

    (b) The address of the principal business and office of each of the Reporting Persons is 357 Tehama Street, Floor 3, San Francisco, California 94103.

     

    (c) EcoR1’s principal business is to serve as the general partner and investment adviser to investment funds, including among others to Qualified Fund and Capital Fund (together, the “Funds”).

     

    Each of the Fund’s principal business is to make investments in securities.

     

    Mr. Nodelman’s principal occupation is as an investor and to serve as a member and the manager of EcoR1.

     

    (d), (e) During the last five years, none of the Reporting Persons (i) has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    All of the Ordinary Shares reported herein were purchased by the Funds for an aggregate purchase price of $335,728,561 including fees and expenses. The source of funds used by the Funds to purchase such Ordinary Shares was derived from the capital of the Funds.

     

    Unless noted above, no part of the purchase price for such Ordinary Shares was borrowed by any Reporting Person for the purpose of acquiring, holding, trading or voting any securities discussed in this Item 3.

     

     

     

     

    Item 4. Purpose of Transaction.

     

    The Reporting Persons believe that the securities of the Issuer are deeply undervalued and represent an attractive investment opportunity, and have invested in the Ordinary Shares based on their belief in the long-term value of the Issuer.

     

    The Reporting Persons intend to communicate with the Issuer’s management and board of directors (the “Board”) about a variety of topics relating to the Issuer’s performance, business, operations, strategic opportunities and governance, including Board composition.

     

    The Reporting Persons intend to review their investments in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the outcome of any discussions referenced above, the Issuer’s financial position and strategic direction, actions taken by the Issuer’s management and the Board, price levels of the Ordinary Shares, other investment opportunities available to the Reporting Persons, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may from time to time and at any time in the future take or engage in various plans, actions or transactions with respect to the investment in the Issuer as they deem appropriate, including, without limitation, purchasing additional Ordinary Shares, disposing of Ordinary Shares, acquiring other financial instruments that are based upon or relate to the value of the Ordinary Shares, selling or obtaining financing on some or all of their beneficial or economic holdings, engaging in hedging or similar transactions with respect to securities that are based upon or relate to the value of the Ordinary Shares, or proposing or considering, or changing their intention with respect to, one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D.  

     

    Item 5. Interest in Securities of the Issuer.

     

    (a), (b) EcoR1 and Mr. Nodelman each may be deemed to beneficially own an aggregate of 6,505,890 Ordinary Shares (the “Subject Shares”), representing approximately 9.9% of the outstanding Ordinary Shares based on 65,897,071 Ordinary Shares outstanding as of December 31, 2023, as reported in the Issuer’s Form 20-F. Qualified Fund may be deemed to beneficially own an aggregate of 6,121,338 of the Subject Shares, representing approximately 9.3% of the outstanding Ordinary Shares. Capital Fund may be deemed to beneficially own an aggregate of 384,552 of the Subject Shares, representing approximately 0.6% of the outstanding Ordinary Shares.

     

    EcoR1, as the general partner of each of the Funds, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all the Subject Shares. Mr. Nodelman may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all the Subject Shares. Each of the Funds may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) only the Subject Shares that it beneficially owns.

     

    (c) No transactions in the Ordinary Shares were effected by the Reporting Persons during the past 60 days.

     

    (d) The Reporting Persons have the right to receive dividends from, and the proceeds from the sale of, the Subject Shares. No other person is known to the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Subject Shares.

     

    (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    EcoR1 acts as the investment adviser to the Funds pursuant to limited partnership agreements providing to EcoR1 the authority, among other things, to invest the funds of such Funds in Ordinary Shares, to vote and dispose of Ordinary Shares and to file this statement on behalf of such Funds. Pursuant to such limited partnership agreements, EcoR1 is entitled to allocations based on assets under management and realized and unrealized gains. Pursuant to such limited partnership agreements, EcoR1 is entitled to fees based on assets under management and realized and unrealized gains.

     

     

     

     

    The Reporting Persons may, from time to time, enter into and dispose of swaps, options or other derivative transactions with one or more counterparties that are based upon the value of the Ordinary Shares, which transactions may be significant in amount. The profit, loss and/or return on such contracts may be wholly or partially dependent on the market value of the Ordinary Shares.

     

    On August 23, 2024, the Reporting Persons entered into a Joint Filing Agreement in which the Reporting Persons agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer to the extent required by applicable law. The Joint Filing Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    Except as disclosed in this Schedule 13D, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons (or to the knowledge of the Reporting Persons, any other person referred to in Item 2) and between the Reporting Persons (or to the knowledge of the Reporting Persons, any other person referred to in Item 2) and any other person with respect to any securities of the Issuer.

     

    Item 7. Material to be Filed as Exhibits.

     

    Exhibit 99.1 Joint Filing Agreement, dated August 23, 2024, among the Reporting Persons.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: August 23, 2024 EcoR1 CAPITAL, LLC
       
      By: /s/ Oleg Nodelman
        Name: Oleg Nodelman
        Title: Manager
       
    Date: August 23, 2024 OLEG NODELMAN
       
      By: /s/ Oleg Nodelman
        Oleg Nodelman
       
    Date: August 23, 2024 EcoR1 CAPITAL FUND QUALIFIED, L.P.
       
      By: EcoR1 Capital, LLC, General Partner
       
      By: /s/ Oleg Nodelman
        Name: Oleg Nodelman
        Title: Manager
       
    Date: August 23, 2024 EcoR1 CAPITAL FUND, L.P.
       
      By: EcoR1 Capital, LLC, General Partner
       
      By: /s/ Oleg Nodelman
        Name: Oleg Nodelman
        Title: Manager

     

     

     

    Get the next $GLPG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GLPG

    DatePrice TargetRatingAnalyst
    2/14/2025$31.00 → $22.00Equal-Weight → Underweight
    Morgan Stanley
    11/20/2024Hold → Reduce
    Kepler
    9/9/2024$24.00Market Perform
    Leerink Partners
    8/2/2024Outperform → Mkt Perform
    Raymond James
    3/28/2024$41.00 → $31.00Neutral → Underperform
    BofA Securities
    3/7/2024$38.00Equal-Weight
    Morgan Stanley
    8/24/2023Buy → Neutral
    Citigroup
    5/5/2023Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $GLPG
    Financials

    Live finance-specific insights

    See more
    • Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

      First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -

      4/23/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

      Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028 Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel cell therapies for cancers of high unmet need Management to host conference call tomorrow, February 13, 2025, at 14:00 CET / 8:00 am ET Mechelen, Belgium; February 12, 2025, 22:01 CET; regulated information – G

      2/12/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

      Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncologyManagement to host conference call today at 14:00 CET / 8:00 am ET MECHELEN, Belgium – January 8, 2025 – 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GL

      1/8/25 1:30:00 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

      First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -

      4/23/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos Announces Executive Leadership Updates

      Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo  Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the next 12 months and plans to continue as Chair of the Board of Directors, ensuring leadership continuity and long-term strategic guidance Mechelen, Belgium; April 21, 2025, 22:10 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today makes two executive leadership announcements. In line with its planned separation

      4/21/25 4:10:00 PM ET
      $GLPG
      $NMRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025

      Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced the departure of its CFO and COO, Thad Huston, effective as of August 1, 2025. Mr. Huston has decided to leave the company and return to the U.S. for personal and professional reasons. Mr. Huston joined Galapagos NV in 2023 from Kite Pharma, Inc., to support Galapagos' transformation into a cell therapy company. The company expects to announce Mr. Huston's successor in the coming months.Paul Stoffels1, MD, CEO and Chair of the B

      4/15/25 1:30:00 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $GLPG
    Leadership Updates

    Live Leadership Updates

    See more
    • Amendment: SEC Form SC 13G/A filed by Galapagos NV

      SC 13G/A - GALAPAGOS NV (0001421876) (Subject)

      11/12/24 9:55:16 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Galapagos NV

      SC 13D/A - GALAPAGOS NV (0001421876) (Subject)

      10/8/24 4:35:06 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Galapagos NV

      SC 13D - GALAPAGOS NV (0001421876) (Subject)

      8/23/24 4:01:26 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

      Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders' Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company.  The annual report for the financial year 2024, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF. The annual 2024 Form 20-F filing with the SEC is available at www.sec.gov/edgar. Galapagos has the honor to invite its shareholders, holders of subscription rights, Board members, and

      3/27/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

      Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024. Mr. Nodelman replaces Mr. Dan G. Baker who stepped down on October 6, 2024. The addition of Mr. Nodelman marks an important step in Galapagos' ongoing efforts to engage with shareholders and continue to execute on our Forward, Faster strategy to accelerate innovation and create near-and long-term value.  "We are pleased to welcome Oleg Nodelman to the Galapagos Board," said Dr. Paul Stoffels, Galapagos' CEO and Chair of the Board of Direc

      10/7/24 1:00:00 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings

      Publication of annual report for financial year 2023Annual Shareholders' Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary Shareholders' Meeting resolutions include approval of renewal of authorized capital and issuance of Gilead Subsequent Warrant B Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders' Meetings (AGM and EGM) to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm (CET) and 3:00 pm (CET), respectively, at the registered office of t

      3/28/24 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    SEC Filings

    See more
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      4/29/25 4:44:24 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      4/23/25 5:19:27 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Galapagos NV

      6-K - GALAPAGOS NV (0001421876) (Filer)

      4/21/25 5:30:59 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Galapagos NV downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously

      2/14/25 8:06:36 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galapagos NV downgraded by Kepler

      Kepler downgraded Galapagos NV from Hold to Reduce

      11/20/24 7:41:53 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Galapagos NV with a new price target

      Leerink Partners initiated coverage of Galapagos NV with a rating of Market Perform and set a new price target of $24.00

      9/9/24 7:50:07 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care